���构特征与受体作用机制 — Explained

By Editorial Desk · published 2026-03-31 · last reviewed 2026-04-27 · Wiki

This is a working overview of 白蛋白结合, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Storage, Handling, and Analytical Verification

Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.

Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.

Semaglutide at a glance

Mechanism and Pharmacological Class

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

Related pages on this site

• Optimized update
• Automated reference
• Scalable archive
• Material primer
• Connected toolkit
• Verified report
• Optimized guide
• Scheduled notes

Molecular Background and Drug Class

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Supporting material

== Afferent inputs == The PVN receives afferent inputs from many brain regions and different parts of the body, by hormonal control. Among these, inputs from neurons in structures adjacent to the anterior wall of the third ventricle (the "AV3V region") carry information about the electrolyte composition of the blood, and about circulating concentrations of such hormones as angiotensin and relaxin, to regulate the magnocellular neurons. Inputs from the brainstem (the nucleus of the solitary tract) and the ventrolateral medulla carry information from the heart and stomach. Inputs from the hippocampus to the CRH neurones are important regulators of stress responses. Inputs from neuropeptide Y-containing neurons in the arcuate nucleus coordinate metabolic regulation (via TRH secretion) with regulation of energy intake. Specifically, the projections from the arcuate nucleus seem to exert their effect on appetite via MC4R-expressing oxytocinergic cells of the PVN. Inputs from suprachiasmatic nucleus about levels of lighting (circadian rhythms). Inputs from glucose sensors within the brain stimulate release of vasopressin and corticotropin-releasing hormone from parvocellular neurosecretory cells.

Direct or tubed flaps involve having the flap connected to both the donor and recipient sites simultaneously, forming a bridge. This allows blood to be supplied by the donor site while a new blood supply from the recipient site is formed. Once this happens, the bridge can be disconnected from the donor site if necessary, completing the transfer. A free flap has the blood supply cut and then reattached microsurgically to a new blood supply at the recipient site.

Irreversible inhibitors covalently bind to an enzyme, and this type of inhibition can therefore not be readily reversed. Irreversible inhibitors often contain reactive functional groups such as nitrogen mustards, aldehydes, haloalkanes, alkenes, Michael acceptors, phenyl sulfonates, or fluorophosphonates. These electrophilic groups react with amino acid side chains to form covalent adducts. The residues modified are those with side chains containing nucleophiles such as hydroxyl or sulfhydryl groups; these include the amino acids serine (that reacts with DFP, see the "DFP reaction" diagram), and also cysteine, threonine, or tyrosine. Irreversible inhibition is different from irreversible enzyme inactivation. Irreversible inhibitors are generally specific for one class of enzyme and do not inactivate all proteins; they do not function by destroying protein structure but by specifically altering the active site of their target. For example, extremes of pH or temperature usually cause denaturation of all protein structure, but this is a non-specific effect. Similarly, some non-specific chemical treatments destroy protein structure: for example, heating in concentrated hydrochloric acid will hydrolyse the peptide bonds holding proteins together, releasing free amino acids. Irreversible inhibitors display time-dependent inhibition and their potency therefore cannot be characterised by an IC50 value.

On 20 September 2014, while speaking to party workers in Multan, Bhutto Zardari said, "I will take back Kashmir, all of it, and I will not leave behind a single inch of it because, like the other provinces, it belongs to Pakistan." The statement was to be the first marking his stance on the Kashmir issue and remarked upon widely in local and international media. On 6 February 2019, Bhutto Zardari met with the Kashmir Council in Washington to express solidarity with the people of Kashmir. During the meeting, he assured the delegation that he would continue to raise his voice against the brutalities of Indian forces against innocent and unarmed Kashmiri people at every available forum both nationally and internationally. He said that loyalty to the cause of Kashmir was in his blood and he would stand with the people of Indian-administered Kashmir in their just struggle for the right to self-determination and freedom from illegal and immoral Indian occupation. On 15 October 2022, after U.S. President Joe Biden referred to Pakistan as "one of the most dangerous nations in the world" and as a carrier of "nuclear weapons without any cohesion" at a Democratic Party fundraiser in California, Bhutto Zardari summoned American diplomat Donald Blome to the Ministry of Foreign Affairs and demanded an explanation as well as called for an official démarche.

In March 1866, a month after the fall, Eddy and her husband (then married for 13 years) moved into an unfurnished room in Lynn. At some point her husband left and Eddy was evicted, unable to pay the $1.50 weekly rent. He appears to have returned briefly—they moved to a boarding house in July, and in August he paid Dr. Cushing's bill from the fall—but the marriage was over. He sent her $200 a year for a time, and they divorced in 1873. Her first student was Hiram Crafts, a shoe worker in whose house she stayed, who advertised for patients himself in May 1867, offering a cure for "Consumption, Catarrh, Scrofula, Dyspepsia and Rheumatism." Eddy asked Crafts to set up a practice with her, but the plan came to nothing. In addition to teaching, Eddy had started to write; toward the end of 1866 she began work on an allegorical interpretation of Genesis, intended as the first volume of a book (never published), The Bible in its Spiritual Meaning. In the summer of 1868, while lodging with spiritualist Sarah Bagley in Amesbury, Eddy advertised for students in a Spiritualist magazine, the Banner of Light, as Mary B. Glover (her first husband's surname). The ad promised a "principle of science" that would heal with "[n]o medicine, electricity, physiology or hygiene required for unparalleled success in the most difficult cases". Sally Wentworth, another Spiritualist, offered Eddy $300-worth of bed and board in Stoughton if Eddy would treat her daughter's lung condition and teach Wentworth the healing method.

Sources: en.wikipedia.org

Notes from published material

=== Severity (staging) and progression (grading) === The most recent (2017) periodontal disease classification uses CAL as a major factor in assessing both Severity and Progression. Alongside other factors like radiographic bone loss and tooth loss. CAL correlates to severity (Staging) as follows.

== History == In 1935, David Shakarian, an Armenian-American businessman, opened a small health food store originally named Lackzoom, in downtown Pittsburgh. He made US$35 on his first day and was able to open a second store within six months. Despite initial setbacks, such as the Ohio River flooding into downtown on St. Patrick's Day that wiped out both stores in 1936, Shakarian persevered and reopened the next year. He later expanded into mail-order sales of health foods, vitamins, and prescription drugs, capitalizing on the growing interest in physical fitness and health consciousness during the 1960s. In the 1960s, the company changed the name of its stores to General Nutrition Centers. Shakarian stepped down as chief executive officer in February 1984 but continued as chairman until his death later that year. Shakarian took GNC public (listed on the NYSE) in the 1980s. Gary Daum was named chief executive office in February 1984. In May 1985, Jerry Horn took on the role. GNC was taken private and sold to Thomas H. Lee Partners a PE investment/management fund in the late 1980s. Thomas Lee ran GNC and took it public prior to selling the company to Royal Dutch Numico and Numico acquired GNC in 1999; it sold GNC to Apollo Management in 2003. Ontario Teachers' Pension Plan and Ares Management bought GNC in 2007. GNC went public in 2011. In 1990, the company considered relocating but a public/private effort retained GNC headquarters in Downtown Pittsburgh.

Under the name "Project TAME", he produced the XA cigarette using palladium. However, in 1978, his project was terminated. Since 1950, the average nicotine and tar content of cigarettes has steadily fallen. Research has shown that the fall in overall nicotine content has led to smokers inhaling larger volumes of smoke per puff.

In its simplest form, nutrient-enriched water is pumped into containers with plants in a growing medium such as Expanded clay aggregate At regular intervals, a simple timer causes a pump to fill the containers with nutrient solution, after which the solution drains back down into the reservoir. This keeps the medium regularly flushed with nutrients and air.

== History == The earliest conception of PeptideAtlas began at the Institute for Systems Biology in the research lab of Ruedi Aebersold by Eric Deutsch and Sharon Chen at the Annotated Peptide Database (APD). The concept was further expanded with additional efforts from Parag Mallick and Frank Desiere. The first instance for an ensemble of human experiments was published in 2004 as the Human PeptideAtlas. The concept was further expanded to many other species over the years with major effort by Nichole King, Zhi Sun, Terry Farrah, and Dave Campbell.

Sources: en.wikipedia.org

Frequently asked questions